Literature DB >> 20335450

The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.

Stine Lyngvi Fougner1, Tove Lekva, Olivera Casar Borota, John K Hald, Jens Bollerslev, Jens Petter Berg.   

Abstract

CONTEXT: Appropriate cell-to-cell adhesion is fundamental for the epithelial phenotype of pituitary cells. Loss of the adhesion protein E-cadherin has been associated with invasiveness, metastasis, and poor prognosis in cancers of epithelial origin. In somatotroph adenomas, a variable and reduced expression of E-cadherin has been demonstrated. In addition, nuclear translocation of E-cadherin was found to correlate with pituitary tumor invasion.
OBJECTIVE: The objective was to examine the protein expression of E-cadherin in somatotroph pituitary adenomas in relation to adenoma size, invasiveness, and somatostatin analog (SMS) efficacy. PATIENTS AND METHODS: Eighty-three patients were included, and 29 were treated preoperatively with SMS. Adenoma E-cadherin protein expression was analyzed by Western blot (61 patients) and immunohistochemistry (IHC) (80 patients) with antibodies directed against both extracellular and intracellular domains (IHC). The acute (direct surgery group) and long-term (preoperatively treated group) SMS responses were evaluated. Baseline tumor volume and invasiveness were measured on magnetic resonance imaging scans.
RESULTS: Membranous E-cadherin was lost in several adenomas. Nine of these were nuclear E-cadherin positive. The E-cadherin protein expression correlated negatively to tumor size and positively to acute SMS response. Low E-cadherin levels (preoperatively treated group only) and loss of membranous E-cadherin correlated to tumor invasiveness. The E-cadherin level correlated positively to tumor reduction after SMS treatment, and adenomas with nuclear E-cadherin staining had lower IGF-I reduction and tumor shrinkage. Preoperatively treated adenomas had reduced E-cadherin protein levels, but the IHC expression was unaltered.
CONCLUSION: Reduced E-cadherin expression may correlate to a dedifferentiated phenotype in the somatotroph pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335450     DOI: 10.1210/jc.2009-2197

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Unusual type of growth hormone-producing pituitary tumor in acromegaly.

Authors:  Satoshi Yamagata; Kazunori Kageyama; Satoru Sakihara; Shozo Yamada; Shinobu Takayasu; Shinji Chikazawa; Naoko Inoshita; Toshiaki Sano; Toshihiro Suda
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.

Authors:  Rosa Maria Paragliola; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  KIT protein expression and mutational status of KIT gene in pituitary adenomas.

Authors:  Olivera Casar-Borota; Stine Lyngvi Fougner; Jens Bollerslev; Jahn Marthin Nesland
Journal:  Virchows Arch       Date:  2012-01-03       Impact factor: 4.064

Review 6.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

8.  Different levels of various glucocorticoid-regulated genes in corticotroph adenomas.

Authors:  Johan Arild Evang; Jens Bollerslev; Olivera Casar-Borota; Tove Lekva; Jon Ramm-Pettersen; Jens Petter Berg
Journal:  Endocrine       Date:  2013-01-13       Impact factor: 3.633

Review 9.  Non-functioning pituitary adenomas: growth and aggressiveness.

Authors:  Kristin Astrid Øystese; Johan Arild Evang; Jens Bollerslev
Journal:  Endocrine       Date:  2016-04-11       Impact factor: 3.633

Review 10.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.